IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer

被引：52

作者：

Emens, L. A. ^{[1
]}

Adams, S. ^{[2
]}

Barrios, C. H. ^{[3
]}

Dieras, V. C. ^{[4
]}

Iwata, H. ^{[5
]}

Loi, S. ^{[6
]}

Rugo, H. S. ^{[7
]}

Schneeweiss, A. ^{[8
]}

Winer, E. P. ^{[9
]}

Patel, S. ^{[10
]}

Henschel, V. ^{[11
]}

Swat, A. ^{[12
]}

Kaul, M. ^{[13
]}

Molinero, L. ^{[14
]}

Chui, S. Y. ^{[15
]}

Schmid, P. ^{[16
]}

机构：

[1] UPMC Hillman Canc Ctr, Dept Med Hematol Oncol, Pittsburgh, PA USA

[2] NYU, Langone Med Ctr, Sch Med, New York, NY USA

[3] Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Invest Ctr, Porto Alegre, RS, Brazil

[4] Ctr Eugene Marquis, Med Oncol, Rennes, France

[5] Aichi Canc Ctr Hosp, Breast Oncol, Nagoya, Aichi, Japan

[6] Peter MacCallum Canc Ctr, Div Res, Translat Breast Canc Genom Lab, Melbourne, Vic, Australia

[7] UCSF, Helen Diller Family Comprehens Canc Ctr, Breast Dept, San Francisco, CA USA

[8] Univ Hosp Heidelberg, German Canc Res Ctr, Heidelberg, Germany

[9] Dana Farber Canc Inst, Med, Boston, MA 02115 USA

[10] Genentech Inc, Med Oncol, San Francisco, CA USA

[11] Genentech Inc, Biostat, San Francisco, CA USA

[12] F Hoffmann La Roche, Clin Sci, Basel, Switzerland

[13] F Hoffmann La Roche, Canc Immunotherapy Clin Safety, Basel, Switzerland

[14] Genentech Inc, Oncol Biomarker Dev, San Francisco, CA 94080 USA

[15] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA

[16] Queen Mary Univ London, Barts Canc Inst, London, England

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.2244

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA16

引用

页码：S1148 / S1148

页数：1

共 50 条

[1] IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
Iwata, H.
Emens, L.
Adams, S.
Barrios, C. H.
Dieras, V.
Loi, S.
Rugo, H. S.
Schneeweiss, A.
Winer, E. P.
Patel, S.
Henschel, V.
Swat, A.
Kaul, M.
Molinero, L.
Chui, S. S.
Schmid, P.
ANNALS OF ONCOLOGY, 2020, 31 : S1261 - S1262
[2] Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
Emens, Leisha A.
Molinero, Luciana
Loi, Sherene
Rugo, Hope S.
Schneeweiss, Andreas
Dieras, Veronique
Iwata, Hiroji
Barrios, Carlos H.
Nechaeva, Marina
Anh Nguyen-Duc
Chui, Stephen Y.
Husain, Amreen
Winer, Eric P.
Adams, Sylvia
Schmid, Peter
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (08): : 1005 - 1016
[3] IMpassion130: Atezolizumab and nab-Paclitaxel Combination in Patients with triple-negative Breast Cancer
Lorenz, Judith
GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (10) : 1076 - +
[4] First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
Emens, L. A.
Adams, S.
Barrios, C. H.
Dieras, V
Iwata, H.
Loi, S.
Rugo, H. S.
Schneeweiss, A.
Winer, E. P.
Patel, S.
Henschel, V
Swat, A.
Kaul, M.
Molinero, L.
Patel, S.
Chui, S. Y.
Schmid, P.
ANNALS OF ONCOLOGY, 2021, 32 (08) : 983 - 993
[5] Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer
Adams, S.
Dieras, V.
Barrios, C. H.
Winer, E. P.
Schneeweiss, A.
Iwata, H.
Loi, S.
Patel, S.
Henschel, V.
Chui, S. Y.
Rugo, H. S.
Emens, L. A.
Schmid, P.
ANNALS OF ONCOLOGY, 2020, 31 (05) : 582 - 589
[6] Subgroup analysis of IMpassion130: Atezolizumab plus nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries
Iwata, H.
Im, S-A.
Sohn, J.
Jung, K. H.
Im, Y-H.
Lee, K. S.
Inoue, K.
Tamura, K.
Wong, A.
Emens, L. A.
Barrios, C. H.
Adams, S.
Schneeweiss, A.
Dieras, V.
Winer, E. P.
Chui, S. Y.
Henschel, V.
Rugo, H. S.
Loi, S.
Schmid, P.
ANNALS OF ONCOLOGY, 2019, 30
[7] IMpassion130: Efficacy in immune biomarker subgroups of atezolizumab plus nab-paclitaxel in patients with triple-negative BC
von Moos, Roger
Emens, Leisha A.
Loi, Sherene
Rugo, Hope S.
Schneeweiss, Andreas
Dieras, Veronique
Iwata, Hiroji
Barrios, Carlos H.
Nechaeva, Marina
Molinero, Luciana
Anh Nguyen Duc
Chui, Stephen Y.
Husain, Amreen
Winer, Eric P.
Adams, Sylvia
Schmid, Peter
SWISS MEDICAL WEEKLY, 2019, 149 : 13S - 14S
[8] IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) plus nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).
Schmid, Peter
Adams, Sylvia
Rugo, Hope S.
Schneeweiss, Andreas
Barrios, Carlos H.
Iwata, Hiroji
Dieras, Veronique
Henschel, Volkmar
Molinero, Luciana
Chui, Stephen Y.
Husain, Amreen
Winer, Eric P.
Loi, Sherene
Emens, Leisha A.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[9] IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) plus nab-paclitaxel (nab-P) vs placebo plus nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC)
Schmid, P.
Adams, S.
Rugo, H. S.
Schneeweiss, A.
Barrios, C. H.
Iwata, H.
Dieras, V.
Hegg, R.
Im, S-A.
Wright, G. S.
Henschel, V.
Molinero, L.
Chui, S. Y.
Funke, R.
Husain, A.
Winer, E. P.
Loi, S.
Emens, L. A.
ANNALS OF ONCOLOGY, 2018, 29 : 707 - 708
[10] Cost-effectiveness analysis of atezolizumab plus nab-paclitaxel for untreated metastatic triple-negative breast cancer
Li, Jiahao
Zhang, Tiantian
Lu, Peiyao
Zhao, Jianfu
Chen, Lin
Jiang, Jie
IMMUNOTHERAPY, 2020, 12 (10) : 705 - 713

← 1 2 3 4 5 →